Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multi-Omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosis.
Kornilov SA, Price ND, Gelinas R, Acosta J, Brunkow ME, Gervasi-Follmar T, Winger RC, Aldershoff D, Lausted C, Troisch P, Smith B, Heath JR, Repovic P, Cohan S, Magis AT. Kornilov SA, et al. Among authors: winger rc. J Neurol Sci. 2024 Nov 10;467:123303. doi: 10.1016/j.jns.2024.123303. Online ahead of print. J Neurol Sci. 2024. PMID: 39561535
Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination.
Kister I, Curtin R, Piquet AL, Borko T, Pei J, Banbury BL, Bacon TE, Kim A, Tuen M, Velmurugu Y, Nyovanie S, Selva S, Samanovic MI, Mulligan MJ, Patskovsky Y, Priest J, Cabatingan M, Winger RC, Krogsgaard M, Silverman GJ. Kister I, et al. Among authors: winger rc. Ann Clin Transl Neurol. 2024 Jul;11(7):1750-1764. doi: 10.1002/acn3.52081. Epub 2024 May 7. Ann Clin Transl Neurol. 2024. PMID: 38713096 Free PMC article.
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis.
Cross AH, Gelfand JM, Thebault S, Bennett JL, von Büdingen HC, Cameron B, Carruthers R, Edwards K, Fallis R, Gerstein R, Giacomini PS, Greenberg B, Hafler DA, Ionete C, Kaunzner UW, Kodama L, Lock C, Longbrake EE, Musch B, Pardo G, Piehl F, Weber MS, Yuen S, Ziemssen T, Bose G, Freedman MS, Anania VG, Ramesh A, Winger RC, Jia X, Herman A, Harp C, Bar-Or A. Cross AH, et al. Among authors: winger rc. JAMA Neurol. 2024 Mar 11;81(4):373-83. doi: 10.1001/jamaneurol.2024.0017. Online ahead of print. JAMA Neurol. 2024. PMID: 38466277 Free PMC article.
Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis.
Barrera B, Simpson H, Engebretson E, Sillau S, Valdez B, Parra-González J, Winger RC, Epperson LA, Banks A, Pierce K, Spotts M, O'Gean K, Alvarez E, Gross R, Piquet AL, Schreiner T, Corboy JR, Pei J, Vollmer TL, Nair KV. Barrera B, et al. Among authors: winger rc. Ann Clin Transl Neurol. 2023 Apr;10(4):579-588. doi: 10.1002/acn3.51745. Epub 2023 Feb 22. Ann Clin Transl Neurol. 2023. PMID: 36811392 Free PMC article. Clinical Trial.
Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity.
Shinoda K, Li R, Rezk A, Mexhitaj I, Patterson KR, Kakara M, Zuroff L, Bennett JL, von Büdingen HC, Carruthers R, Edwards KR, Fallis R, Giacomini PS, Greenberg BM, Hafler DA, Ionete C, Kaunzner UW, Lock CB, Longbrake EE, Pardo G, Piehl F, Weber MS, Ziemssen T, Jacobs D, Gelfand JM, Cross AH, Cameron B, Musch B, Winger RC, Jia X, Harp CT, Herman A, Bar-Or A. Shinoda K, et al. Among authors: winger rc. Proc Natl Acad Sci U S A. 2023 Jan 17;120(3):e2207291120. doi: 10.1073/pnas.2207291120. Epub 2023 Jan 12. Proc Natl Acad Sci U S A. 2023. PMID: 36634138 Free PMC article.
Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapies.
Kister I, Curtin R, Pei J, Perdomo K, Bacon TE, Voloshyna I, Kim J, Tardio E, Velmurugu Y, Nyovanie S, Valeria Calderon A, Dibba F, Stanzin I, Samanovic MI, Raut P, Raposo C, Priest J, Cabatingan M, Winger RC, Mulligan MJ, Patskovsky Y, Silverman GJ, Krogsgaard M. Kister I, et al. Among authors: winger rc. Ann Clin Transl Neurol. 2022 Oct;9(10):1643-1659. doi: 10.1002/acn3.51664. Epub 2022 Sep 27. Ann Clin Transl Neurol. 2022. PMID: 36165097 Free PMC article.
The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome.
Longbrake EE, Hua LH, Mowry EM, Gauthier SA, Alvarez E, Cross AH, Pei J, Priest J, Raposo C, Hafler DA, Winger RC. Longbrake EE, et al. Among authors: winger rc. Mult Scler Relat Disord. 2022 Dec;68:104143. doi: 10.1016/j.msard.2022.104143. Epub 2022 Aug 22. Mult Scler Relat Disord. 2022. PMID: 36031693 Free PMC article.
Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.
Kister I, Patskovsky Y, Curtin R, Pei J, Perdomo K, Rimler Z, Voloshyna I, Samanovic MI, Cornelius AR, Velmurugu Y, Nyovanie S, Kim JJ, Tardio E, Bacon TE, Zhovtis Ryerson L, Raut P, Pedotti R, Hawker K, Raposo C, Priest J, Cabatingan M, Winger RC, Mulligan MJ, Krogsgaard M, Silverman GJ. Kister I, et al. Among authors: winger rc. Ann Neurol. 2022 Jun;91(6):782-795. doi: 10.1002/ana.26346. Epub 2022 Apr 1. Ann Neurol. 2022. PMID: 35289960 Free PMC article.
21 results